Forte Biosciences, Inc.

NasdaqCM FBRX

Forte Biosciences, Inc. Receivables for the quarter ending September 30, 2024

Forte Biosciences, Inc. Receivables is NA for the quarter ending September 30, 2024. Receivables are the amounts owed to the company by customers for goods sold or services rendered.

Key data

Date	Receivables	Inventory	Goodwill	Total Assets

NasdaqCM: FBRX

Forte Biosciences, Inc.

CEO	Dr. Paul A. Wagner Ph.D.
IPO Date	April 13, 2017
Location	United States
Headquarters	3060 Pegasus Park Drive
Employees	11
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.

Key trends

Past 5 years